Distribution of specific somatic mutations among morphologically acceptable and not acceptable tumor specimens.

<p>Acceptable (<i>A</i>) and not acceptable (<i>NA</i>) tumor specimens with mutated (MUT) or wild-type (WT) DNA sequences. (<b>A</b>) Codons 12 and 13 of the K-RAS in mCRC patients. (<b>C)</b> Codon 600 of the BRAF in mMEL patients. (<b>D</b>) Exons 18–21 of EGFR in NSCLC patients. Mutated or wild-type NA tumor specimens at K-RAS (<b>B</b>) and EGFR (<b>E</b>) were further divided into samples with less than 50% (70% before 2011) enriched tumor cells (<i>NA1</i>) and samples with less than 100 tumor cells (<i>NA2</i>) per FFPE tissue section. Different frequencies of mutated/wild-type specimens between <i>NA</i> (<i>NA1</i> and <i>NA2</i>) and <i>A</i> samples did not result statistically significant (p>0.05). X-axis: categories of morphological suitability; y-axis: percent of samples with wild-type or mutated sequences.